| Latest | F'cast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | 2.6% | 4.4% |
| ROCE | 9.1% |
| Latest | F'cast | |
|---|---|---|
| P/E | 40.5 | 25.3 |
| PEG | n/a | 0.4 |
| Pr/Revenue | 1.0 | 1.0 |
| Pr/Book | 2.8 |
| Latest | F'cast | |
|---|---|---|
| Revenue | -0.7% | 0.2% |
| PBT | n/a | 181.2% |
| EPS | n/a | 60.0% |
| DPS | n/a | n/a |
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 30-Jun-08 | 31.02 | (20.24) | (24.80)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Jun-09 | 37.76 | (11.44) | (14.35)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Jun-10 | 40.75 | (0.12) | 0.20p | 57.5 | n/a | n/a | n/a | 0.0% |
| 30-Jun-11 | 41.55 | (2.31) | (0.86)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Jun-12 | 41.28 | 0.64 | 0.25p | 31.0 | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 30-Jun-13 | 41.35 | 1.80 | 0.40p | 25.3 | 0.4 | +60% | n/a | 0.0% |
| 30-Jun-14 | 44.35 | 2.85 | 0.55p | 18.4 | 0.5 | +38% | n/a | 0.0% |
Copyright © 2013 FactSet Research Systems Inc. All rights reserved.
| Grant of Options | 15-May-2013 | 10:20 | RNS |
| Holding(s) in Company | 08-May-2013 | 10:39 | RNS |
| Holding(s) in Company | 08-May-2013 | 10:18 | RNS |
| Allergy Therapeutics ends contract with Lincoln ... | 27-Dec-2012 | ShareCast |
| Chamberlin Chairman invests 75k | 10-Dec-2012 | ShareCast |
| Shanks Chairman buys shares as profits fall | 09-Nov-2012 | ShareCast |
| Allergy drug firm hit by trials setback | 12-Jul-2007 | The Independent |
| Need to Know: Global Business Briefing | 25-Mar-2006 | Times |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 10.13p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 13.50p |
| 52 Week Low | 7.63p |
| Volume | 0 |
| Shares Issued | 409.87m |
| Market Cap | £41.50m |
| Beta | 0.61 |
| RiskGrade | 90 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| Strong Buy | 0 |
| Buy | 1 |
| Neutral | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 1 |

| No dividends found |
| Finance Director | Ian D Postlewaite |
| CEO | Manuel Llobet |
You are here: research